Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action

By M. Pescovitz. American Journal of Transplantation, 2006

608 citations recorded by the source corpus.

Rituximab, chimeric anti‐human CD20, is approved for treatment of B‐cell lymphoma in adults. It is being used experimentally in other various immune‐related diseases such as immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and rheumatoid arthritis. In transplant recipients, it is used for treatment of post‐transplant lymphoproliferative disease, to anecdotally reduce pre‐formed anti‐HLA and anti‐ABO antibodies and for the prevention and treatment of acute rejection. This article primarily reviews the science behind rituximab: its history, pharmacokinetics and potential mechanism of action. A need for controlled clinical trials is clearly indicated before the widespread use of this drug in transplant.

Subfields: Genetics, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/6db754ead9fdca142ff53ff7112500fadf52005a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Martina Anzaghe
2. Yen-Ju Lin
3. S. Schülke

Citations in the corpus

• Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “In treated patients repeated administration of rituximab effectively depletes CD20 positive B cells via either (1) antibody-dependent cellular cytotoxicity, (2) complement-mediated cytotoxicity, or (3) apoptosis [285].”